Vimarsana
Biggest News Aggregation in the World

Page 6 - Susan Ringdal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Susan Ringdal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Susan Ringdal Today - Breaking & Trending Today

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva® - Vimarsana News

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®

/PRNewswire/ -- Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license...

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva® - Vimarsana News

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®

/PRNewswire/ -- Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license...

Hikma appoints Patrick Genestin to lead Generics Business Development - Vimarsana News

Hikma appoints Patrick Genestin to lead Generics Business Development

Hikma appoints Patrick Genestin to lead Generics Business Development News provided by Share this article Share this article LONDON, June 9, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that Patrick Genestin has been appointed Vice President, Business Development, Generics. Mr. Genestin brings to Hikma more than 25 years of experience in the pharmaceutical industry as a results-driven executive with strong financial, business development and M&A experience. He will be based at the company's US headquarters in Berkeley Heights, ...

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg - Vimarsana News

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg Important new option for reversing opioid overdoses News provided by Share this article Share this article LONDON, April 30, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the approval of KLOXXADO TM (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric...

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Result of AGM - Vimarsana News

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Result of AGM

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...